Jeffrey D. Whitman
YOU?
Author Swipe
View article: A-275 Evaluation of Dried Blood Spots for Serological Detection of Chagas Disease
A-275 Evaluation of Dried Blood Spots for Serological Detection of Chagas Disease Open
Background Chagas Disease (CD) is a vector-borne parasitic infection of Trypanosoma cruzi, endemic to the Americas. Sequela of this infection include cardiomyopathy and gastrointestinal dysmotility disorders. Approximately 6 million people…
View article: Three Year Results from the United States FDA Prospective Multicenter Clinical Study of the EVO/EVO+ Implantable Collamer Lens
Three Year Results from the United States FDA Prospective Multicenter Clinical Study of the EVO/EVO+ Implantable Collamer Lens Open
This 3-year study confirmed the central port design of the EVO ICL functions effectively to allow physiologic flow of aqueous humor, thus eliminating the requirement for preoperative PI and reducing the incidence of ASC and pupillary block…
View article: A<i>Trypanosoma cruzi</i>Trans-Sialidase Peptide Demonstrates High Serological Prevalence Among Infected Populations Across Endemic Regions of Latin America
A<i>Trypanosoma cruzi</i>Trans-Sialidase Peptide Demonstrates High Serological Prevalence Among Infected Populations Across Endemic Regions of Latin America Open
Infection by Trypanosoma cruzi , the agent of Chagas disease, can irreparably damage the cardiac and gastrointestinal systems during decades of parasite persistence and related inflammation in these tissues. Diagnosis of chronic disease re…
View article: Adaptation of Chagas Disease Screening Recommendations for a Community of At-risk HIV in the United States
Adaptation of Chagas Disease Screening Recommendations for a Community of At-risk HIV in the United States Open
Chagas disease (CD), caused by Trypanosoma cruzi, is underdiagnosed in the United States. Improved screening strategies are needed, particularly for people at risk for life-threatening sequelae of CD, including people with human immunodefi…
View article: Chagas Disease Diagnostic Practices at Four Major Hospital Systems in California and Texas
Chagas Disease Diagnostic Practices at Four Major Hospital Systems in California and Texas Open
Background Chagas disease (CD) is a parasitic disease that affects ∼300 000 people living in the United States. CD leads to cardiac and/or gastrointestinal disease in up to 30% of untreated people. However, end-organ damage can be prevente…
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis KMT2A/MLL1-rearranged (MLL…
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Data from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL
View article: Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>–Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALL Open
Supplementary Figure from Surface Proteomics Reveals CD72 as a Target for In Vitro–Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL